treatment as planned or as instructed by the clinician. This current protocol, may not want to discuss, but, I share the information with the authors. 7. One additional point. I think the criteria for participants could be strengthened. Are you going to exclude primary progressive aphasia? Is there a cognitive level of performance? I ask that, as coexisting cognitive deficits could affect ability to follow the protocol.
REVIEWER
Elaine Toomey National University of Ireland Galway REVIEW RETURNED 30-Aug-2018
GENERAL COMMENTS
General comments • In general, I really like this study and the excellent focus by the authors on being so comprehensive in relation to their fidelity protocol! I have a few comments which I think could really enhance this paper and its use both for other researchers and also for the authors themselves for use later on after the trial. I have selected Minor Revisions, mostly just in relation to restructuring and providing further clarification I think.
• There a good bit ofverlap and lack of clarity within NIHBCC domains section -hard to follow in places as some bits are mentioned earlier in the paper, but not discussed in depth until later (e.g. fidelity criteria, competency skills etc)
• Not clear if paper is about development of protocol, i.e. the protocol is the output, or just about providing the protocol. If the latter, I actually think the former (i.e. how the protocol was developed) would potentially be of greater use. Not being super clear on this makes the structure of the paper somewhat hard to follow. Regardless of which, perhaps providing more information on the development of the protocol would be of use for the audience.
• Lack of detail about specifics -ie not knowing what the active ingredients are, not knowing what the fidelity criteria are -limits the usefulness of the protocol, i.e. will not be possible to compare final trial procedures to intended as per this protocol. This is alluded to in places (i.e. treatment receipt section provides some info on essential criteria) but is not consistent with other NIHBCC domains and could be provided earlier.
• What stage is the trial at currently? How and when will the fidelity results be reported, i.e. before, during or after trial results? Specific comments Abstract:
• P1 line 29-30: Would suggest using an existing definition of treatment fidelity and/or referencing this definition to help avoid too many definitions being used in the literature.
• P1 line 41 and p2 line 39: 'NIH BCC fidelity framework (Treatment Fidelity Workshop of the National Institutes of Health Behaviour Change Consortium)' -would perhaps just change this to National Institutes of Health Behaviour Change Consortium treatment fidelity framework for simplification -same with the Strengths and Limitations section • P1 Line 45-46 'Within aphasia intervention studies, monitoring and reporting of treatment fidelity is still relatively rare' -and enhancing? In line with previous sentences that address all three aspects Strengths and limitations:
• P2 line 41: 'The fidelity protocol sets out the checks and balances in place' -sounds a bit colloquial, suggest rewording to be more precise and clear about what it does Introduction:
• 'Treatment fidelity is a complex, multi-faceted evaluative process that can be captured in two simple questions: "Was the intervention delivered as intended?" and "How was this monitored and measured?" (Davidson et al., 2003) .' -these questions I think somewhat unhelpfully focus the fidelity • P7 16-19 'A number of steps were taken to support participants' comprehension: the treatment materials were developed based on aphasia-friendly guidelines including simplified language, larger font, key words in bold, use of photographs/diagrams/pictures to support the written text, and blank space' -when were these steps taken? One thing that isn't fully clear to me is whether this paper is about the development of the protocol, or whether this has been reported elsewhere and this paper is simply about providing the fidelity protocol that was developed. If the latter hasn't been done -i.e. the steps taken to develop the protocol and then the resultant protocol, then that may actually be a more informative and helpful paper…. Procedure for monitoring and enhancing treatment delivery:
• There seems to be a lot of repetition between this section and the preceding ones -suggest restructuring these sections to try and make this clearer and easier to follow • P8 line 39 -what is the underlying theory? Table 1: • Would be helpful to know which components of the NIHBCC checklist were not considered and why, e.g. Use of experts or protocol review group to determine whether the intervention protocol reflects the underlying theoretical model or clinical guidelines, Assessment of provider skill acquisition etc. Also -was it the Borrelli 2005 checklist or the updated Borrelli 2011 version used?
• Treatment receipt -NIHBCC 2011 checklist also addresses the assessment of recipient understanding and skills -have you a plan to assess this? Table 2 Overall, this is a very well written study and quite pertinent to the field of aphasiology. I have very minor edits/comments. I look forward to the publication and future results. Thank you.
Comments:
1. Page 4 line 13-I would caution the authors that aphasia is not SOLELY caused by stroke. The authors wrote "aphasia (a language disability caused by stroke)." Your project may be enrolling only individuals with aphasia post-stroke, but there are other causes. Thank you for this point. Our intention was to define aphasia within the context of the ASK study, where we recruit individuals with post-stroke aphasia. While aphasia has multiple aetiologies, in this paper we want to keep the focus on fidelity. Therefore, we have revised the sentence as follows: "The purpose of this paper is to describe the development of a fidelity protocol for the Action Success Knowledge (ASK) study, a current cluster randomised trial investigating an early mood intervention for people with post-stroke aphasia (an acquired language and communication disability)."
2.
The introduction and background in the protocol refers to "therapists", but does not address if this is just speech language pathologists, or crosses over different rehabilitation therapists. Would like clarification as to the choice of the term "therapists". The consistency of the term "speech pathologists" does not seem to occur until the page 5. Also, a suggestion to be consistent with "speech language pathologist" is recommended. In the Introduction and Background sections, "therapists" refers generally to allied health therapists. This has been revised either to the specific discipline or to "therapy provider".
3. Page 7 line 11-12 the sentence is unclear: " Therapy providers are usually staff at the participating clusters whose caseload mean they are best placed to screen, recruit, and provide the treatment to study participants." This sentence has been revised: "Therapy is provided either by a private therapist employed as a casual employee of the trial, or by speech pathology staff at the participating clusters. In the case of the latter, suitable therapists are identified as those whose usual duties bring them into contact with patients with aphasia for screening, recruitment and administration of the study treatment".
4.
Page 7 line 53, there is a infinitive "to meet" when it should just read "do not meet" This has been revised.
5.
Page 8-really appreciate the section "Treatment receipt". Thank you.
6. Page 8-"Enactment of treatment skills": I appreciate the effort in standardizing the training. This is critical in the whole fidelity process. The focus of the treatment delivery is the speech pathologists' delivery, in the case of client directed treatment. In terms of "enactment", in homework tasks, it seems odd that the authors return to "completion" or doing the task, instead of doing the task as directed. Although not essential, to change this section, a suggestion is to actually see if the homework carryover is performed as directed, hence exploring fidelity carryover. Ball, de Riesthal and Steele (2018) , did discuss that in client directed home practice, fidelity can be from the client's perspective-did the client follow the treatment as planned or as instructed by the clinician. This current protocol, may not want to discuss, but, I share the information with the authors. We appreciate the reviewer's suggestions. As we describe in the paper, monitoring enactment of treatment skills is notoriously difficult to achieve. The paper has been updated to make it clear that enactment was supported but not directly monitored. This is an important lesson for future studies and has certainly been an important learning curve for us.
7.
One additional point. I think the criteria for participants could be strengthened. Are you going to exclude primary progressive aphasia? Is there a cognitive level of performance? I ask that, as coexisting cognitive deficits could affect ability to follow the protocol. Individuals with diagnosed primary progressive aphasia are excluded from the study. The ASK study protocol has been published separately and specifies the eligibility criteria. This has been added to the first paragraph of the Introduction.
Reviewer: 2
Reviewer Name: Elaine Toomey
In general, I really like this study and the excellent focus by the authors on being so comprehensive in relation to their fidelity protocol! I have a few comments which I think could really enhance this paper and its use both for other researchers and also for the authors themselves for use later on after the trial. I have selected Minor Revisions, mostly just in relation to restructuring and providing further clarification I think.
Thank you.
Please leave your comments for the authors below
• Lack of detail about specifics -ie not knowing what the active ingredients are, not knowing what the fidelity criteria are -limits the usefulness of the protocol, i.e. will not be possible to compare final trial procedures to intended as per this protocol. This is alluded to in places (i.e. treatment receipt section provides some info on essential criteria) but is not consistent with other NIHBCC domains and could be provided earlier. Development of fidelity processes within the ASK trial:
• This section isn't the easiest to follow, as there seem to be overlaps between sections and materials, new definitions introduced. Not knowing what the specifics of the intervention (e.g. what the 'active ingredients' actually are, what the actual intended dose is) are also adds to the confusion. I think this section could be restructured a bit to make it easier to read.
• I know you don't want to risk unblinding participants, but it's a bit difficult to know what the fidelity protocol actually is (so that it could be compared to what actually happened) when we don't know the full details -e.g. what the treatment dose was actually specified a-priori to be? This goes for a lot of the other sections too • P6 line 20: 'and how to tailor the treatment to suit the needs of an individual participant whilst not deviating from the essential components of the treatment' -this is really key and a key part of what I think the protocol would need to cover, but very difficult to achieve and also hard to understand how it will be done without more detail -i.e. how do you intend providers to achieve this? How do you intend to teach them how to do this? What are the essential components? What is acceptable tailoring, what is unacceptable?
• P6 line 56 -what are the fidelity criteria?
• Great to have the active ingredient information but I think this is needed earlier -some of my previous comments are based on not having this information until later in the paper The reviewer's final comment somewhat negates the previous comments calling for the criteria to be shared; therefore, we have combined these comments. We appreciate that the fidelity criteria should be referenced earlier in the paper. Therefore, we have revised the paper so that Tables 2 and 3 appear much earlier (page 5); this ensures the reader is aware that the full fidelity criteria for treatment delivery are disclosed within the paper. We have also added Section 1 and 2 to provide clearer signposting within the paper: 'Within the current paper, Section 1 will describe the fidelity processes within the ASK trial and how these processes map onto the NIH BCC framework. The fidelity criteria used to monitor therapy delivery for both the experimental and attention control arms are included (Tables 2 and 3) . Section 2 will focus specifically on fidelity monitoring of therapy delivery. Here, we describe the procedure for reviewing intervention sessions, such as the procedure for therapy providers to submit audio-video recordings. Figure 1 provides a schematic of this procedure'.
• There a good bit of overlap and lack of clarity within NIHBCC domains section -hard to follow in places as some bits are mentioned earlier in the paper, but not discussed in depth until later (e.g. fidelity criteria, competency skills etc) The structure of the paper has been revised using the headings: 'Section 1' and 'Section 2'. Explanatory sentences have been added to signpost the reader through the paper, for example, on page 5: 'Within the current paper, Section 1 will describe the fidelity processes within the ASK trial and how these processes map onto the NIH BCC framework. The fidelity criteria used to monitor therapy delivery for both the experimental and attention control arms are included (Tables 2 and 3) . Section 2 will focus specifically on fidelity monitoring of therapy delivery. Here, we describe the procedure for reviewing intervention sessions, such as the procedure for therapy providers to submit audio-video recordings. Figure 1 provides a schematic of this procedure'.
• Not clear if paper is about development of protocol, i.e. the protocol is the output, or just about providing the protocol. If the latter, I actually think the former (i.e. how the protocol was developed) would potentially be of greater use. Not being super clear on this makes the structure of the paper somewhat hard to follow. Regardless of which, perhaps providing more information on the development of the protocol would be of use for the audience. We appreciate the reviewer's feedback on this point. It is not our intention to present the development of the fidelity tool; rather, we wish to focus on implementing a fidelity protocol that maps onto the NIH BCC's recommendations. This is in line with the journal's guidelines to "provide a documented record of a researcher's plan of action, detailing in advance a study's rationale, methodology and analyses.... that ensures greater transparency in the research process".
• What stage is the trial at currently? How and when will the fidelity results be reported, i.e.
before, during or after trial results?
A sentence has been added to the first paragraph of the Introduction to address this question: 'Data collection is currently ongoing; the results of the fidelity monitoring will be reported at the end of data collection, as part of the trial results paper'.
Specific comments Abstract:
To our knowledge, it is not customary to cite references in the Abstract; therefore the requested change has not been made. In the Introduction, we have appropriately referenced existing definitions of treatment fidelity.
• P1 line 41 and p2 line 39: 'NIH BCC fidelity framework (Treatment Fidelity Workshop of the National Institutes of Health Behaviour Change Consortium)' -would perhaps just change this to National Institutes of Health Behaviour Change Consortium treatment fidelity framework for simplification -same with the Strengths and Limitations section. Thank you for the suggestion. This has been revised in the paper.
• P1 Line 45-46 'Within aphasia intervention studies, monitoring and reporting of treatment fidelity is still relatively rare' -and enhancing? In line with previous sentences that address all three aspects This has been revised as suggested. The sentence now reads: 'Within aphasia intervention studies, the monitoring, enhancing and reporting of treatment fidelity is still relatively rare'.
Strengths and limitations:
• P2 line 41: 'The fidelity protocol sets out the checks and balances in place' -sounds a bit colloquial, suggest rewording to be more precise and clear about what it does. This has been revised to: 'The fidelity protocol details the strategies used to monitor and enhance fidelity within delivery of a complex intervention'.
Introduction:
• 'Treatment fidelity is a complex, multi-faceted evaluative process that can be captured in two simple questions: "Was the intervention delivered as intended?" and "How was this monitored and measured?" (Davidson et al., 2003) .' -these questions I think somewhat unhelpfully focus the fidelity only on delivery, rather than training, receipt and the other NIHBCC domains -wold suggest rephrasing this to be in line with the broader conceptualisation of fidelity as NIHBCC have advocated and as you have addressed within your study This sentence has been revised to delete the quested and to include the broader concept of fidelity: 'Treatment fidelity is a complex, multi-faceted evaluative process. The aim is to increase scientific confidence in the findings of behavioural intervention studies by monitoring and enhancing the reliability and validity of the intervention(s) delivered'.
• P3. line 26: Suggest you outline more specifically what you mean by 'fidelity strategies' -i.e. to enhance, assess, and also -what single method is referring to here The choice of the phrase 'fidelity strategies' was inspired by Borrelli, et al. (2005) who refer to fidelity as 'methodological strategies' (p.852). To avoid any confusion, we have revised the sentence:
'Despite the methodological and translational benefits, fidelity monitoring has been used inconsistently…'
• P3 line 29: 'The concept of monitoring treatment fidelity arose from drug trials' -would suggest referencing this statement as other research has posited that it arose in psychotherapy literature in the 70's Our original sentence was based on the need to monitor drug dosage administered in drug trials. As there is no clear study to reference this, the sentence has been deleted.
• P3 line 47 -is this 14% referring to reporting assessing/enhancing fidelity (ie reporting use of strategies to enhance/assess), or reporting the actual results of the fidelity assessment? Hinckely and Douglas (2013) found 14% of reviewed aphasia studies reported treatment fidelity. We believe this is clear in the current wording and have not revised this statement.
• P4 line 7 -'differences in therapists' decision making suggests the need for closer monitoring of sites throughout the study' -could you explain this a bit further? Here we are referring to the previous line about significant differences in the time individual providers spend on specific therapy component. The sentence has been revised to clarify this: 'differences in therapy providers decision making (regarding how much time to spend on specific therapy components) suggest…'
• P4 line 16-18 'Descriptive manuals of the intended treatments were provided (Bowen et al., 2012a; Bowen et al., 2012b) but care was taken not to prescribe a universal experimental treatment (Bowen et al., 2012b)' -more detail could be helpful here as not clear how both aspects align or what universal experimental treatment means exactly The sentence has been revised: 'Descriptive manuals of the intended treatments were provided… but care was taken not to prescribe a one-size-fits-all treatment for the experimental arm'.
• The gap and resultant need for this work in aphasia is very well made, but how does it compare to other areas? Are there any other studies in similar areas that might inform/help inform how this study is done? For example the Lorencatto et al 2016 Affinitie protocol https://implementationscience.biomedcentral.com/articles/10.1186/s13012-016-0528-x or the Toomey et al 2016 fidelity protocol https://www.ncbi.nlm.nih.gov/pubmed/26939605 studies may be of use for next stages. Thank you for this point. We acknowledge that fidelity monitoring work is continuing in other fields such as physiotherapy and we appreciate that we have much to learn from each other. However, in this paper, it is not our intention to present a review of fidelity monitoring or to compare methods within aphasia studies to other fields. Therefore, we have drawn on examples of fidelity monitoring that are more closely related to the interventions delivered within the ASK trial.
Overview of ASK treatments:
• 'Minimum of 3, maximum of 8' -what will determine this? It's quite a big variation in dose, so if it is essential that this dosage can be tailored, then what are the criteria for tailoring? I.e. when is it 'acceptable/intended' to be 3 as opposed to 8? The prescribed dose is outlined in the trial protocol; we do not believe the fidelity protocol study is the appropriate place to explain dose. The protocol paper has been published elsewhere and we reference it throughout the paper. Furthermore, we have added a reference to the protocol paper to the first paragraph of the Introduction.
• The content of the modules are subject to ongoing investigation within the trial; to reduce the risk of unblinding assessors and/or participants, the content of treatment will not be discussed in detail in this paper. It seems that no revision was requested here.
• Study design: One of the NIHBCC main aspects of the 'study design' domain is around the theoretical underpinnings -this is something that I think is missing from the study at present -what theory is the study based on? Thank you for highlighting this lack of clarity. Details on the theoretical underpinning of the interventions has been added to the paper; see page 5: 'Theoretical underpinnings of the ASK interventions'.
• Study design: Any measurement of fidelity planned for the training domain? I.e. measuring staff understanding etc afterwards, measuring fidelity of delivery of training? Measuring whether staff actually access booster sessions or not?
• Table 1 : Treatment receipt -NIHBCC 2011 checklist also addresses the assessment of recipient understanding and skills -have you a plan to assess this? These components of fidelity monitoring are not part of the current ASK fidelity protocol. We agree that they are important components and would add important information in future studies. As the reviewer requested in a separate comment, we have added a column to Table 1 to indicate which components were incorporated into the ASK fidelity monitoring and which were not.
Training:
• You mention a lot of manuals and plans -i.e. assessor manual, treatment manual -perhaps a table outlining all the specific materials/strategies to be used more simply would be helpful? There is one assessor manual and one treatment manual within each arm.
Study design:
• What training do the control arm providers get?
Providers in the control arm receive the same amount and type of training as those in the experimental arm. This has been clarified in the paper: 'Within both arms, the treatment manuals contain information…' and 'Training for therapy providers across the trial arms is standardised…' Treatment delivery:
• P6 line 25: 'Fidelity was defined as the extent to which the therapist administered the treatment as planned and the competency with which the treatment was delivered' -do you mean fidelity of delivery? Relates to my earlier point about broader conceptualisation of fidelity, need to be specific and clear throughout to avoid ambiguity The sentence has been revised: 'Fidelity of treatment delivery was defined as the extent to which the therapist administered the treatment as planned…'
• P6 line 29: According to previous definitions, I think competency is more about how well the provider delivers the treatment, or the quality of delivery, not treatment drift. Drift could occur in relation to delivery of content also -or adherence? This also is not consistent with how competency is referred to later in the 'Procedure for monitoring and enhancing treatment delivery' section We agree with the Reviewer and have revised this in the paper: '…assessment of treatment delivery includes monitoring and improving how therapy providers a) deliver only the target treatment (differentiation); b) acquire and maintain the required skills set (competency); and c) deliver the intended treatment components (adherence)'.
• P6 line 43: Who is the ASK fidelity monitor? As with earlier statement, perhaps a table outlining the actors and people involved and their roles within the protocol could be useful and help with clarity The role of fidelity monitored is carried out by the trial managers. This has been added to the paper.
Treatment receipt:
• P7 16-19 'A number of steps were taken to support participants' comprehension: the treatment materials were developed based on aphasia-friendly guidelines including simplified language, larger font, key words in bold, use of photographs/diagrams/pictures to support the written text, and blank space' -when were these steps taken? One thing that isn't fully clear to me is whether this paper is about the development of the protocol, or whether this has been reported elsewhere and this paper is simply about providing the fidelity protocol that was developed. If the latter hasn't been done -i.e. the steps taken to develop the protocol and then the resultant protocol, then that may actually be a more informative and helpful paper…. To answer the Reviewer's first question, the treatment materials were developed prior to commencement of the intervention. This has been added to the paper: 'The aphasia-friendly treatment materials were developed by the research team before any participant commenced treatment'.
To answer the Reviewer's second question, the protocol paper has been published elsewhere and has been referenced throughout the submitted paper.
Procedure for monitoring and enhancing treatment delivery:
• There seems to be a lot of repetition between this section and the preceding ones -suggest restructuring these sections to try and make this clearer and easier to follow We have deleted some of the detail within this section, to avoid repetition. We have retained the section overall, so as to explain how the operational procedure of fidelity monitoring within the ASK trial. • Would be helpful to know which components of the NIHBCC checklist were not considered and why, e.g. Use of experts or protocol review group to determine whether the intervention protocol reflects the underlying theoretical model or clinical guidelines, Assessment of provider skill acquisition etc. Also -was it the Borrelli 2005 checklist or the updated Borrelli 2011 version used? Table 1 has been revised to show more clearly which BCC recommendations were implemented in the ASK trial, and which were not. The recommendations in Table 2 are synthesised from Bellg et al. (2004) , Borrelli (20110 and Borrelli et al. (2005) . • This information would potentially be more helpful alongside the manual of intended content? We are not in a position to publish the intervention manuals as the trial is ongoing. Publication of the intervention manuals before data collection has finished would risk unblinding our Blinded Assessors. • First box is incomplete Thank you for pointing this out. This has been corrected.
• Where does the online booster training fit within this? Perhaps if the figure covered the whole fidelity protocol this might be more helpful Figure 1 focuses on fidelity assessment of treatment delivery and receipt; therefore we have not added the booster training to the Figure. However, we appreciate the request to provide more information on this training and have added this to the main body of text: "Online refresher/booster training is available to all staff; this can be requested by the staff member at any time. Typically, staff access booster training following a period of leave". This information has also been added to Table 1. • Perhaps be clear about the method of assessment -e.g. audio/video/direct obs The first box has been updated to state: 'For a therapist's first participant, the Fidelity Monitor watches 100% of audio-video recordings of the goal-setting and the first intervention session'
VERSION 2 -REVIEW

REVIEWER
Elaine Toomey National University of Ireland Galway, Ireland REVIEW RETURNED 14-Nov-2018
GENERAL COMMENTS
Thank you for addressing my comments so well, I do not have any further comments and look forward to seeing this in publication.
